11073-10418 INR Purpose Monitor the coagulation of blood for those on anti-coagulation therapy Monitor for therapeutic levels of medication Monitor for.

Slides:



Advertisements
Similar presentations
What characteristics of patients and local health systems are associated with ED utilization?
Advertisements

Common/shared responsibilities between jobs.
Type 2 diabetes Implementing NICE guidance 2009 NICE clinical guideline 87.
Evidence-Based Management of Anticoagulant Therapy
The Home INR Study (THINRS): Home INR Monitoring as Effective as Clinic-Based Care AK Jacobson, MD American Heart Association 2008 Scientific Sessions:
Australian Guidance Document Number xx Cathy Thomas Professional Representation OT Australia WA.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
General Approach of Haemostasis Prothrombin Time (Continue) Lecture 5:
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
Health Science Career Cluster Pathways Objective Remember elements of healthcare career decision making.
By: Maria Ashmore, Leveque Derisca, Prystal Golphin.
WARFARIN AN OVERVIEW.
Decision Support for Quality Improvement
Chapter 1- “Diversity” “In higher education they value diversity of everything except thought.” George Will.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
CDRM Project Diabetes Management Stefan Stadler – November 2009.
Essential Equipment and Software for Athletic Training Focus: To use these essential equipment's and software to help prevent and treat injuries for athletes.
Neurology APTT, PTT, PT, INR. Neurology APTT, PTT, PT, INR.
In Which Areas Have Clinical Pharmacists Been the Most Successful in Patient Care ? Hospital inpatient unit (wards) –Therapeutic drug monitoring –Anticoagulation.
INR for warfarin monitoring ©bpac nz, October 2006.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
So You Want to Do CDS A C-Level Introduction to Clinical Decision Support.
BY: KIROLOS-FADY SAEED RN & ARNP. RN 2 & 4 Year degree (AA or BSN) largest employment--2.5 million jobs.
  The prothrombin time is therefore the time required for the plasma to clot after an excess of thromboplastin and an optimal concentration of calcium.
Assessment of Patient Knowledge Regarding Drugs Prescribed and Dispensed in Some Health Insurance Outpatient Clinics in Alexandria.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Documentation of Care Provided Patient’s care - who should do it? WHY DOCUMENT? When should it occur? Where should it be documented? How should it be documented?
1 Vulnerable Time During Patient Transitions Terrence O’Malley, MD Medical Director, Non-Acute Care Services Partners HealthCare
1 Vulnerable Time During Patient Transitions Terrence O’Malley, MD Medical Director, Non-Acute Care Services Partners HealthCare
Dr. S. Parthasarathy MD DA DNB PhD (physio) Mahatma Gandhi medical college and research institute, puducherry – India Prothrombin time.
Health Management Information Systems
Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.
Serbia Health Project – Additional Financing Training for Trainers on AR-DRG, Република Србија МИНИСТАРСТВО ЗДРАВЉА Linda Best
History of the Prothrombin Time and Development of the INR Leon Poller European Concerted Action on Anticoagulation.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes.
Pharmacy is not less important than medicine
Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.
Section VII. Home BP Measurement 2015 Canadian Hypertension Education Program Recommendations.
RARE BEST PRACTICES COURSE ROMA (Feb ) Euro-HSP Madrid 2015 May 30 Jean Bénard May 31, GA 2015 Madrid.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
Spotlight Case Watch the Warfarin!. 2 Source and Credits This presentation is based on the July 2011 AHRQ WebM&M Spotlight Case –See the full article.
Local Enhanced Service Care bundles Dr Andy Kilpatrick, Clinical Lead.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.
Date of download: 7/11/2016 From: The International Normalized Ratio (INR) for Monitoring Warfarin Therapy: Reliability and Relation to Other Monitoring.
Evidence-Based Management of Anticoagulant Therapy
1st International Online BioMedical Conference (IOBMC 2015)
Pharmaceutical Care Plan
ASPIRE Workshop 5: Application of Biostatistics
ASPIRE Workshop 5: Application of Biostatistics
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Aug, 2016.
Michael Malone M.D., Ali Ward RN, Office Manager
Warfarin Prescribing.
Objective 3.01 Understanding Diagnostic and Therapeutic Services
General Approach in Investigation of Hemostasis
Pharmacogenomics Genes and Drugs.
Introduction To Medical Technology
Pharmacy practice experience I
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Point-of-Care vs Laboratory INR Testing to Optimize Anticoagulation Management.
ASPIRE Workshop 5: Application of Biostatistics
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Objective 3.01 Understanding Diagnostic and Therapeutic Services
Hospital pharmacy.
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

INR Purpose Monitor the coagulation of blood for those on anti-coagulation therapy Monitor for therapeutic levels of medication Monitor for safe levels of therapy Advise on adjustment to therapy Titrate to therapeutic level Approach Coagulability measured from sample of arterial or venous blood using thromboplastin to determine prothrombin time (PT) Different thromboplastins available and will give different results INR - International Normalized Ratio Determines coagulation time compared to normalized reference Allows values from different thromboplastins to be compared Given as a simple number

Use Cases Health care professional testing and therapy management Regular measurement to maintain therapeutic level by a health care professional Management by the health care professional Self testing Regular measurement to maintain therapeutic level by the patient Measurements sent to health care professional for advice Warnings if out of therapeutic range or if severely out of range Self management Regular measurement to maintain therapeutic level by the patient Patient advised how to self manage Device may have target level, information on drug and dose and intelligence to advise on medication change

Use Cases Patient Care Pathway Patient is under medical care of primary physician (will vary by country and system) who has responsibility for regime Measurements reviewed and advice may be given to alter medication Warnings if out of therapeutic range and medical intervention required Warnings if severely out of range

Data Requirements (this defines the data that the INR must provide in some way) INR - required Date and time stamp - required Target therapeutic range – required INR value out of therapeutic range – required INR value at dangerous clinical level – required INR value out of clinical range – required Status of measurement – required Batch/code number – required Device alarm conditions - required Serial # - required Prothrombin Time (PT) - supplemental Quick Value – supplemental International Sensitivity Index (ISI) – supplemental Medication – supplemental Review period - supplemental Recommended new level of medication – supplemental Device type / model - supplemental Manufacturer - supplemental User Identifier – supplemental Additional information - supplemental

Data Objects (defines the objects needed to satisfy the data requirements) INR – required Target therapeutic range – required INR value out of therapeutic range – required INR value at dangerous clinical level – required INR value out of clinical range – required Batch/code number – required Status of measurement - required Device alarm conditions – required Prothrombin Time (PT) - supplemental Quick Value – supplemental International Sensitivity Index (ISI) – supplemental Medication – supplemental Review period - supplemental Recommended new level of medication – supplemental Additional information - supplemental

Data Attributes (specifies data that already is defined as an attribute or otherwise) Date and time stamp – required Serial # - required Device type / model - supplemental Manufacturer - supplemental User Identifier – supplemental Following may be included in Status of Measurement INR value out of therapeutic range – required* INR value at dangerous clinical level – required* INR value out of clinical range – required*

Data Objects (defines the objects needed to satisfy the data requirements grouped and ordered logically) Clinical Data Prothrombin Time (PT) - supplemental Quick Value – supplemental INR – required Batch/code number – required International Sensitivity Index (ISI) – supplemental Status of measurement – required* Monitoring Target therapeutic range – required Management Medication – supplemental Review period - supplemental Recommended new level of medication – supplemental Additional information – supplemental Device Device alarm conditions – required

Data Objects

References 1.Lutze G. Useful facts about coagulation. Mannheim: Roche Diagnostics GmbH, (data on file) 2.Wagner C, Dati F. Thromboplastinzeit (german article). In: Thomas L, ed. Labor und Diagnose: TH-Books Verlagsgesellschaft, 2000; Kovaks MJ et al. Thromb Haemost 1994; 71:

Domain Information Model